Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Iovance Biotherapeutics, Inc.

< Previous 1 2 Next >
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Tickers IOVA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.